Revenio: Not a one-trick pony
Revenio is known as the global beacon of tonometers but these days the company is a noteworthy challenger in more extensive ophthalmic health technology. Imaging tools (previous CenterVue) play an increasing role in future growth and HOME products, as well as software business offer longer term growth promises. Business is growing very profitably, the market has sound growth drivers, and the products have strong competitive advantages. In addition, the company has an excellent track record of its ability to create value with investments in product development, structural reorganization, and new long-term growth templates
Login required
This content is only available for logged in users
Revenio Group
Revenio är verksamt inom medicinteknik. Inom koncernen återfinns forskning och utveckling av tryckmätningsteknik som används vid behandling av ett flertal sjukdomar såsom glaukom, osteoporos, hudcancer samt astma. Verksamhet innehas på global nivå och drivs via flertalet dotterbolag med vardera affärsinriktning. Bolagets huvudkontor ligger i Vantaa.
Read more on company pageKey Estimate Figures08.06.2021
2020 | 21e | 22e | |
---|---|---|---|
Omsättning | 61,1 | 79,3 | 102,5 |
tillväxt-% | 23,41 % | 29,94 % | 29,21 % |
EBIT (adj.) | 19,2 | 27,2 | 37,1 |
EBIT-% | 31,44 % | 34,34 % | 36,19 % |
EPS (adj.) | 0,58 | 0,82 | 1,10 |
Utdelning | 0,32 | 0,40 | 0,55 |
Direktavkastning | 0,64 % | 1,44 % | 1,98 % |
P/E (just.) | 86,56 | 33,78 | 25,36 |
EV/EBITDA | 61,53 | 26,13 | 18,60 |